Parissis J - Search Results

1

Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.

Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, Černý V, Comin-Colet J, Crespo-Leiro MG, Delgado JF, Édes I, Eremenko AA, Farmakis D, Fedele F, Fonseca C, Fruhwald S, Girardis M, Guarracino F, Harjola VP, Heringlake M, Herpain A, Heunks LMA, Husebye T, Ivancan V, Karason K, Kaul S, Kivikko M, Kubica J, Masip J, Matskeplishvili S, Mebazaa A, Nieminen MS, Oliva F, Papp JG, Parissis J, Parkhomenko A, Põder P, Pölzl G, Reinecke A, Ricksten SE, Riha H, Rudiger A, Sarapohja T, Schwinger RHG, Toller W, Tritapepe L, Tschöpe C, Wikström G, Lewinski DV, Vrtovec B, Pollesello P. Papp Z, et al. Among authors: parissis j. J Cardiovasc Pharmacol. 2020 Jul;76(1):4-22. doi: 10.1097/FJC.0000000000000859. J Cardiovasc Pharmacol. 2020. PMID: 32639325 Free PMC article. Review.

2

Anti-inflammatory effects of levosimendan in decompensated heart failure: impact on weight loss and anemia.

Parissis JT, Farmakis D, Kremastinos DT. Parissis JT, et al. Am J Cardiol. 2005 Apr 1;95(7):923-4. doi: 10.1016/j.amjcard.2004.11.018. Am J Cardiol. 2005. PMID: 15781038 No abstract available.

3

Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart.

Paraskevaidis IA, Parissis JT, Th Kremastinos D. Paraskevaidis IA, et al. Curr Med Chem Cardiovasc Hematol Agents. 2005 Jul;3(3):243-7. doi: 10.2174/1568016054368232. Curr Med Chem Cardiovasc Hematol Agents. 2005. PMID: 15974888 Review.

4

Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure.

Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, Venetsanou K, Lekakis J, Kremastinos DT. Parissis JT, et al. Am J Cardiol. 2005 Aug 1;96(3):423-6. doi: 10.1016/j.amjcard.2005.03.092. Am J Cardiol. 2005. PMID: 16054474 Clinical Trial.

5

Levosimendan for the treatment of acute heart failure syndromes.

Parissis JT, Filippatos G, Farmakis D, Adamopoulos S, Paraskevaidis I, Kremastinos D. Parissis JT, et al. Expert Opin Pharmacother. 2005 Dec;6(15):2741-51. doi: 10.1517/14656566.6.15.2741. Expert Opin Pharmacother. 2005. PMID: 16316312 Review.

6

Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?

Parissis JT, Farmakis D, Kremastinos DT. Parissis JT, et al. Eur J Heart Fail. 2006 Mar;8(2):215; author reply 218. doi: 10.1016/j.ejheart.2006.01.003. Epub 2006 Jan 27. Eur J Heart Fail. 2006. PMID: 16442844 Free article. No abstract available.

7

Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.

Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT. Adamopoulos S, et al. Am J Cardiol. 2006 Jul 1;98(1):102-6. doi: 10.1016/j.amjcard.2006.01.068. Epub 2006 May 6. Am J Cardiol. 2006. PMID: 16784930 Clinical Trial.

8

Functional electrical stimulation improves endothelial function and reduces peripheral immune responses in patients with chronic heart failure.

Karavidas AI, Raisakis KG, Parissis JT, Tsekoura DK, Adamopoulos S, Korres DA, Farmakis D, Zacharoulis A, Fotiadis I, Matsakas E, Zacharoulis A. Karavidas AI, et al. Eur J Cardiovasc Prev Rehabil. 2006 Aug;13(4):592-7. doi: 10.1097/01.hjr.0000219111.02544.ff. Eur J Cardiovasc Prev Rehabil. 2006. PMID: 16874150 Clinical Trial.

9

Tissue Doppler imaging analysis at pre-cardioversion time predicts recurrent atrial fibrillation: a 12-month follow-up study.

Paraskevaidis IA, Vartela V, Tsiapras D, Iliodromitis EK, Parissis J, Farmakis D, Kremastinos DT. Paraskevaidis IA, et al. Among authors: parissis j. J Cardiovasc Electrophysiol. 2006 Sep;17(9):1005-10. doi: 10.1111/j.1540-8167.2006.00566.x. J Cardiovasc Electrophysiol. 2006. PMID: 16948745

10

Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.

Parissis JT, Adamopoulos S, Farmakis D, Filippatos G, Paraskevaidis I, Panou F, Iliodromitis E, Kremastinos DT. Parissis JT, et al. Heart. 2006 Dec;92(12):1768-72. doi: 10.1136/hrt.2006.079707. Heart. 2006. PMID: 17105880 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

401 results

Search Page